Objective To evaluate the mucosal immunity effects of H3N2 influenza vaccine lyophilized liposomes, and to compare the antibody levels in different parts of the respiratory tract. Method Experimental mice were divided into the influenza vaccine non-liposome group, the influenza vaccine lyophilized liposome group, positive control group and negative control group (n = 5). 4(xg and 6(xg hemagglutinin (H3N2 subtype) per mouse were delivered intranasally to the influenza vaccine non-liposome group and the influenza vaccine lyophilized liposome group mice, with intraperitoneally injected influenza vaccine non-liposome group and lyophilized liposome group mice as the positive control, and PBS intraperotoneal injection group as the negative control. The indirect ELISA method was used to measure the serum IgG and respiratory mucosal slgA levels after 28 days of immunization. Result The respiratory slgA level of the influenza vaccine lyophilized liposome group was higher than that of the influenza vaccine non-liposome group (P < 0. 05). The slgA level of upper respiratory tract (nasopharynx) was significantly higher than that of the lower respiratory tract (lung) (P < 0. 01). Conclusion The influenza vaccine lyophilized liposome could effectively induce humoral immunity and mucosal immunity of respiratory. The mucosal immunity effect of upper respiratory tract was higher thanthat of lower respiratory tract. But comparing with non-liposome vaccine ,liposome performs well on lower respiratory tract in terms of adjuvant effect.
NETL
NSTL
维普
万方数据
